Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.
Acute myeloid leukaemia (AML) statistics
New cases of acute myeloid leukaemia, 2014, UK
Deaths from acute myeloid leukaemia, 2014, UK
- There were around 3,100 new cases of acute myeloid leukaemia (AML) in the UK in 2014, that’s around 8 cases diagnosed every day.
- AML accounts for less than 1% of all new cases in the UK (2014).
- In males, there were around 1,800 cases of AML diagnosed in the UK in 2014.
- In females, there were around 1,300 cases of AML diagnosed in the UK in 2014.
- Almost 6 in 10 (55%) acute myeloid leukaemia cases in the UK each year are diagnosed in people aged 70 and over (2012-2014).
- Incidence rates for acute myeloid leukaemia in the UK are highest in people aged 85+ (2012-2014).
- Since the early 1990s, acute myeloid leukaemia incidence rates have increased by more than a quarter (28%) in the UK. The increase is similar in males where rates have increased by almost a third (30%), and in females where rates have increased by around a fifth (21%).
- Over the last decade, acute myeloid leukaemia incidence rates have increased by 8% in the UK, though this includes an increase in males (10%) and stable rates in females.
- 1 in 200 men and 1 in 255 women will be diagnosed with AML during their lifetime.
- Leukaemia (AML) in England is more common in males living in the most deprived areas. There is no association for females.
- An estimated 6,100 people who had previously been diagnosed with acute myeloid leukaemia (AML) were alive in the UK at the end of 2010.
- There were around 2,500 acute myeloid leukaemia (AML) deaths in the UK in 2014, that’s around 7 deaths every day.
- AML accounts for 2% of all cancer deaths in the UK (2014).
- In males in the UK, there were around 1,500 AML deaths in 2014.
- In females in the UK, there were around 1,100 AML deaths in 2014.
- Around half (51%) of acute myeloid leukaemia (AML) deaths in the UK each year are in people aged 75 and over (2012-2014).
- Mortality rates for AML in the UK are highest in people aged 85-89 (2012-2014).
- Since the early 1970s, acute myeloid leukaemia (AML) mortality rates have increased by more than four-fifths (84%) in the UK. The increase is larger in males (99%), than in females (60%).
- Over the last decade, AML mortality rates have increased by almost a tenth (8%) in the UK, however this includes an increase (11%) for males and stable rates for females.
- Leukaemia (AML) deaths in England are not associated with deprivation.
- Five-year relative survival for acute myeloid leukaemia (AML) in men is similar to the European average in England, Wales and Scotland.
- Five-year relative survival for acute myeloid leukaemia (AML) in women is below the European average in England but similar to the European average in Scotland.
- ‘Two-week wait’ standards are met by all countries, and ‘31-day wait’ is met by all but England for acute leukaemia.
- Almost 95% of patients had a ‘very good’ or ‘excellent’ patient experience.
- Around 8 in 10 patients are given the name of their Clinical Nurse Specialist.
The latest statistics available for acute myeloid leukaemia (AML) in the UK are incidence 2014 and mortality 2014. Reliable survival data for the UK is currently not available.
European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.
Lifetime risk estimates were calculated using incidence, mortality, population and all-cause mortality data for 2010-2012 due to the small number of cases.
Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. AML is part of the group 'Acute leukaemia' for cancer waiting times data. Codes vary per country but broadly include: acute lymphoblastic, myeloid and monocytic leukaemia and some other leukaemia of specific or unspecified cell type.
Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.
Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.
You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:
Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.
When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or
We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.